To evaluate TiME signature in human tumors, we analyzed mRNA sequencing data obtained from pretreatment tumor biopsies (GEO GSE78220) in metastatic melanoma patients treated with anti–PD-1 antibodies (n = 27) (43). The gene discussed is PDCD1; the disease is metastatic melanoma.